Chen S J, Rader D J, Tazelaar J, Kawashiri M, Gao G, Wilson J M
Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
Mol Ther. 2000 Sep;2(3):256-61. doi: 10.1006/mthe.2000.0122.
Adeno-associated viral vectors were used to deliver the gene for very-low-density lipoprotein (VLDL) receptor (VLDLR) to liver of a murine model of familial hypercholesterolemia (FH). Infusion of adeno-associated virus-VLDLR into the portal circulation of FH mice resulted in a 40% reduction in serum cholesterol and triglyceride that was stable for the duration of the study (30 weeks). Fractionation of serum lipids revealed a reduction of both VLDL and low-density lipoprotein. Expression of transgene-derived VLDLR was confirmed in livers of recipient animals by Western blot analysis and immunohistochemistry; vector DNA was present at 1 copy/cell. Vector-treated animals had significantly less lipid accumulation in liver and reduced atherosclerosis in the aorta.
使用腺相关病毒载体将极低密度脂蛋白(VLDL)受体(VLDLR)基因传递至家族性高胆固醇血症(FH)小鼠模型的肝脏。将腺相关病毒-VLDLR注入FH小鼠的门静脉循环后,血清胆固醇和甘油三酯降低了40%,在研究期间(30周)保持稳定。血清脂质分级显示VLDL和低密度脂蛋白均减少。通过蛋白质印迹分析和免疫组织化学在受体动物肝脏中证实了转基因衍生的VLDLR的表达;载体DNA以1拷贝/细胞的形式存在。接受载体治疗的动物肝脏中的脂质积累明显减少,主动脉中的动脉粥样硬化减轻。